Johnson & Johnson Innovative Medicine
Pharmaceutical Companies of Johnson and Johnson
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of 8.9 years Additional findings from pooled analysis of three phase 3 studies show treatment with ibrutinib has the potential to achieve comparable overall survival to the...
TALVEY (talquetamab) demonstrated highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
24-month overall survival rate of 67% achieved with talquetamab 0.8mg/kg biweekly dosing in the phase 1/2 MonumenTAL-1 study 14 June 2024 – Beerse, Belgium – Janssen-Cilag International NV, a Johnson & Johnson company announced today that long-term data from the phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple...
Updated phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease
At 5 years, 67% of patients were progression-free, with overall survival at 96% for all treated patients 14 June 2024 – Beerse, Belgium – (GLOBE NEWSWIRE) – Janssen-Cilag International NV, a Johnson & Johnson company, today announced updated findings from the phase 2 CAPTIVATE study evaluating fixed-duration (FD) IMBRUVICA (ibrutinib) in combination with venetoclax (I+V)...
CARVYKTI▼ (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma
73% reduction in risk of disease progression or death seen with cilta-cel in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy 3 June 2024 -- Beerse, Belgium -- Janssen-Cilag International, a Johnson & Johnson company announced today results from a subgroup analysis of the phase 3...
TECVAYLI▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma
New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing Separate analyses from the MajesTEC-1 and OPTec studies are the first to underscore the opportunity for outpatient administration of teclistamab. 3 June 2024 -- Beerse, Belgium -- Janssen-Cilag International NV, a Johnson...
DARZALEX (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma
88% of transplant-eligible patients achieved a complete response or better, and 47% of patients sustained MRD-negativity for longer than one year with daratumumab subcutaneous formulation-based regimens in the phase 3 PERSEUS study 7.5 years median overall survival achieved with daratumumab-based regimen in phase 3 MAIA final survival analysis is the longest reported in patients ineligible...
Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT▼ (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer
Submission is supported by data from the phase 3 PALOMA-3 study featured at the American Society of Clinical Oncology (ASCO) Annual Meeting New formulation showed non-inferiority to intravenous administration in fourth positive phase 3 amivantamab study Longer overall survival, progression-free survival and duration of response shown with subcutaneous amivantamab; featured in Best of ASCO 2024....
RYBREVANT▼ (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark phase 3 MARIPOSA data featured in an oral presentation at ASCO 2024. 31 May 2024 -- Beerse, Belgium -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced new data from the...
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations 5 May 2024 -- Beerse, Belgium -- Janssen-Cilag International, a Johnson & Johnson company, announced today updated results from an open-label, multicentre, multi-cohort phase 1 study of the safety and efficacy of TAR-210, an...
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer
New data from phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98% achieving a CR within 12 weeks TAR-200 provides durable CRs in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC) with carcinoma in situ – a disease area with limited treatment options for patients. 3 May 2024...
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
0800 731 5550
